Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
NCT00984997Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 1993
- Primary completion
- Jun 2007
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) and etoposide in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Locoregional Control at 10 years. Started Oct 1993; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)etoposide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00984997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984997.